On Tuesday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $21.05 which represents a slight increase of $2.26 or 12.03% from the prior close of $18.79. The stock ...

U.S. stocks on Wednesday slipped, as investors digested a slight acceleration in the Federal Reserve's favorite inflation gauge. Here are some of Wednesday's biggest stock movers: Biggest stock ...

($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall Street trimming price targets after the ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target ...

RBC Capital analyst Luca Issi maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price target of ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference ...

Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET. Company Participants. Vince Anzalone - VP, IR Chris Anzalone - Preside ...